Larkspur Biosciences is a technology company.
Larkspur Biosciences has raised $36.0M across 1 funding round.
Larkspur Biosciences has raised $36.0M in total across 1 funding round.
Larkspur Biosciences has raised $36.0M in total across 1 funding round.
Larkspur Biosciences's investors include Acrew Capital, CRV, GreatPoint Ventures, Polaris Partners, Section 32.
Larkspur Biosciences is a biotechnology company developing precision immunotherapies and small molecule drugs targeting cancer-intrinsic factors to overcome immune evasion in tumors, particularly in oncology like colorectal cancer (CRC).[1][3][4][5] Founded in 2020 (with public launch in 2023), it serves healthcare providers and patients resistant to existing therapies by using its proprietary LarkX bioinformatics platform, which integrates machine learning, tumor genetics, and immune phenotypes to identify responders and advance programs like LRK-4189, an oral degrader of PIP4K2C for microsatellite stable (MSS) CRC.[1][2][3][5] The company raised $35.5M in seed/Series A funding in May 2023 from investors including Polaris Partners, Takeda Ventures, and 3E Bioventures Capital, positioning it in the R&D/clinical stage with 11-50 employees in Watertown, MA.[2][3]
Larkspur Biosciences emerged from groundbreaking academic research by founders Lewis Cantley, PhD (cancer cell biology), Nathanael Gray, PhD (biochemistry/chemical biology), and Vijay K. Kuchroo, DVM, PhD (immunology), who identified tumor bottlenecks subverting immune responses.[3][6] Building on their labs' discoveries in precision targets for cancer and autoimmunity, the company launched publicly in 2023 with $35.5M financing, initially focusing on a genetically- and immunologically-defined CRC subtype identifiable via biopsy for proof-of-concept.[2][3] Early traction came from this founder expertise—each a prolific scientist and serial entrepreneur—culminating in CEO Catherine Sabatos-Peyton, PhD's leadership to translate lab insights into therapies for non-responders to standard immunotherapies.[3][6]
Larkspur rides the precision oncology wave, merging AI-driven bioinformatics with immunotherapy to tackle immune evasion—a key reason many patients fail checkpoint inhibitors or relapse.[1][3] Timing aligns with surging demand for tumor-intrinsic therapies amid CRC's high unmet need (e.g., MSS subtype resistance) and advances in degraders/small molecules, fueled by market forces like rising cancer incidence and AI's role in target discovery.[2][4][5] It influences the ecosystem by validating founder-led biotech models, enriching CRC pipelines, and expanding "fitness gene" strategies to other indications, potentially accelerating companion diagnostics and responder-enriched trials.[3][5]
Larkspur is poised to advance LRK-4189 into clinic for MSS CRC proof-of-concept, with LarkX enabling pipeline expansion to shared evasion signatures across cancers.[3][5] Trends like AI-biotech convergence, degrader tech, and personalized immuno-oncology will propel growth, especially as funding supports R&D amid biotech resurgence. Its influence may evolve by setting benchmarks for tumor fitness modulation, delivering first-in-class options for immunotherapy non-responders, and amplifying founder legacies in outsmarting cancer's immune escape. This positions Larkspur as a precision immunotherapy frontrunner in oncology's next chapter.[1][2][4]
Larkspur Biosciences has raised $36.0M across 1 funding round. Most recently, it raised $36.0M Series A in May 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2023 | $36.0M Series A | Acrew Capital, CRV, GreatPoint Ventures, Polaris Partners, Section 32 |